Advertisement
The Body: The Complete HIV/AIDS Resource
Follow Us Follow Us on Facebook Follow Us on Twitter Download Our App
Professionals >> Visit The Body PROThe Body en Espanol
  
  • Email Email
  • Comments Comments
  • Printable Single-Page Print-Friendly
  • Glossary Glossary

Medical News

Gilead Sciences, Johnson & Johnson Plan HIV Collaboration

July 27, 2011

A Johnson & Johnson unit, Tibotec Pharmaceuticals, is partnering with Gilead Sciences Inc. to develop a pair of HIV combination treatments. The companies said they have agreed to collaborate on a pill that combines J & J's Prezista with cobicistat, a Gilead drug candidate that is designed to boost the effectiveness of other antiretroviral medicines. In addition, the firms are negotiating on combining Prezista with Gilead's HIV drug Emtriva, along with another Gilead candidate called GS 7340. GS 7340 is a version of Viread, an older Gilead drug. Tibotec would be responsible for formulating the first treatment as well as for manufacturing, regulatory matters and sales. Gilead would lead development and sales of the second product. The deal will not be considered complete until the companies come to an agreement on the second combination pill.

Back to other news for July 2011

Adapted from:
Boston Globe
06.28.2011


  
  • Email Email
  • Comments Comments
  • Printable Single-Page Print-Friendly
  • Glossary Glossary

This article was provided by CDC National Prevention Information Network. It is a part of the publication CDC HIV/Hepatitis/STD/TB Prevention News Update.
 
See Also
More on HIV Medications
Drugs in Development: Other New Drugs
Advertisement:
Find out how a Walgreens specially trained pharmacist can help you

No comments have been made.
 

Add Your Comment:
(Please note: Your name and comment will be public, and may even show up in
Internet search results. Be careful when providing personal information! Before
adding your comment, please read TheBody.com's Comment Policy.)

Your Name:


Your Location:

(ex: San Francisco, CA)

Your Comment:

Characters remaining:

Tools
 

Advertisement